Research programme: recombinant Bifidobacterium anticancer therapeutics - Anaeropharma Science

Drug Profile

Research programme: recombinant Bifidobacterium anticancer therapeutics - Anaeropharma Science

Alternative Names: Anti-CTLA4 scfv - Anaeropharma Science; Anti-PD-1 and Anti-CTLA4 scfv - Anaeropharma Science; APS-001; BEST-CD; BifidobactErial Selective Targeting-Cytosine Deaminase therapy; FGF2 producing B. longum - Anaeropharma Science

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anaeropharma Science
  • Developer Anaeropharma Science; Eisai Co Ltd
  • Class Anti-ischaemics; Antineoplastics; Bacteria; Gene therapies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Fibroblast growth factor replacements; Gene transference; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Peripheral arterial disorders

Most Recent Events

  • 08 Aug 2017 Preclinical trials in Peripheral arterial disorders in Japan (IV) before August 2017 (Anaeropharma Science pipeline, August 2017)
  • 21 Dec 2015 This programme is still in active development
  • 24 Sep 2012 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top